RVT 802

Drug Profile

RVT 802

Alternative Names: RVT-802

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator Duke University
  • Developer Duke University; Enzyvant Sciences
  • Class
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Di George syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Di George syndrome

Most Recent Events

  • 06 Jan 2017 Clinical trials in Di-George syndrome in USA before January 2017
  • 06 Jan 2017 Enzyvant announces intention to submit BLA to US FDA in 2018
  • 06 Jan 2017 RVT 802 receives Orphan Drug status for Di-George syndrome in USA before January 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top